Tratamiento del cáncer de pulmon portador de la mutación del receptor del factor de crecimiento epidérmico
Palabras clave:
eficacia, neoplasias pulmonares, proteínas tirosina quinasa, supervivencia.Resumen
Introducción: El cáncer de pulmón es un problema de salud en el mundo. En el carcinoma de pulmón de células no pequeñas se han identificado la presencia de una serie de alteraciones moleculares entre ellas, la mutación del receptor del factor de crecimiento epidérmico.
Objetivo: Describir el desarrollo y evolución de la terapia con inhibidores tirosina quinasa para el tratamiento de pacientes con carcinoma de pulmón con mutación del receptor del factor de crecimiento epidérmico.
Métodos: Se consultaron las bases de datos, EMBASE, Cochrane y Scopus, así como la plataforma PubMed. Se emplearon términos del Medical Subject Headings (MeSH), se tuvieron en cuenta: Artículos publicados entre el 2014 y el 2023, en idioma español e inglés. Se revisaron un total de 183 artículos y se seleccionaron 52: Artículos de revisión (16) y artículos originales (36), libros de texto (2) y guía de diagnóstico y tratamiento (2).
Desarrollo: El descubrimiento de este gen fue seguido del desarrollo de fármacos inhibidores de la tirosina quinasa, que han permitido evidenciar una mayor eficacia en los pacientes portadores de dicha mutación, en comparación con la quimioterapia, lo cual inició una nueva era en el tratamiento del cáncer de pulmón. A pesar de las excelentes tasas de respuestas y supervivencia la mayoría de los pacientes, desarrollan resistencia adquirida, después de una mediana de supervivencia de 12 meses de iniciado el tratamiento.
Conclusiones: El desarrollo de terapias dirigidas a la mutación del receptor del factor de crecimiento epidérmico, cambió el estándar de tratamiento de los pacientes con cáncer de pulmón de células no pequeñas, que expresan dicha mutación.
Descargas
Los datos de descargas todavía no están disponibles.
Citas
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataran I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 countries [Internet]. CA Cancer J Clin. 2021; 71(3):209-49. DOI: 10.3322/caac.21660
2. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non- small cell lung cancer: Past, present and future [Internet]. World J Clin Oncol. 2021; 12(4):217-37. DOI: 10.5306/wjco.v12.i4.217
3. DeVita VT, Rosenberg SA, Lawrence TS. Cancer Principles & Practice of Oncology. Primer of the molecular biology of cáncer. Third edition. Philadelphia: Editorial Wolters Kluwer; 2021.
4.Wadowska K, Bil-Lula I, Trembecki L, Sliwinska-Mosson M. Genetic markers in lung cancer diagnosis: a review [Internet]. Int J Mol Sci. 2020; 21(13):4569. DOI: 10.3390/ijms21134569
5. Herrera-Juarez M, Serrano-Gomez C, Bote de Cabo H, Paz-Ares L. Targer therapy for lung cáncer: beyong EGFR and ALK [Internet]. Cancer. 2023; 129(12):1803-20. DOI: 10.1002/cncr.34757
6. Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang A, et al. Epidemiologic features of NSCLC gene alterations in Hispanic patients from Puerto Rico [Internet]. Cancers. 2020; 12(12):3492. DOI: 10.3390/cancers12123492
7. Niederhuber J, Armitage J, Doroshow J, Kastan M, Teper J. Abeloff. Oncologíaclínica. 6th edition. España. Editorial Elsevier; 2020.
8. Hubbard SR. EGF receptor inhibition: Attacks on multiple fronts [Internet]. Cancer Cell. 2005; 7(4):287-8. DOI: 10.1016/j.ccr.2005.04.004
9. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al . Epidermal growth factor receptor (EGFR) signaling in cancer [Internet]. Gene. 2006; 366(1):2-16. DOI: 10.106/j.gene.2005.10.018
10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy [Internet]. Nat Rev Cancer. 2004; 4(5):361-70. DOI: 10.1038/nrc1360
11. Dalurzo M, Aviles-Salas A, Soares F, HouY, Li Y, Stroganova A, et al. Testing for EGFR mutations and ALK rearrangements in Advanced Non Small Cell Lung Cancer. Considerations for countries in emerging markets [Internet]. Onco Targets and Therapy. 2021; 14:4671-92. DOI: 10.2147/OTT.S313669
12. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, et al. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests [Internet]. Clin Lung Cancer. 2020; 21(3):e182-e190. DOI: 10.1016/j.cllc.2019.11.006
13. Rao S, Anthony M, Chowdhry N, Kathrotia R, Mishra M, Naithani M, et al. Molecular Characterization of Lung carcinomas: a study on diagnosis, predictive and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India [Internet]. J Carcinog. 2021; 20:17. DOI: 10.4103/jcar_14_21
14. Thomas R,Weihua Z.Rethink of EGFR in Cancer With Its Kinase Independent Function on Board [Internet]. Front Oncol. 2019; 9:800. DOI: 10.3389/fonc.2019.00800
15. Abourehab M, Alqahtani A, Youssif B, Gouda A. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [Internet]. Molecules. 2021; 26(21):6677. DOI: 10.3390/molecules26216677
16. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geftinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma [Internet]. N Engl J Med. 2009; 361(10):947-957. DOI: 10.1056/NEJMoa0810699
17. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinomaof the lung [Internet]. J ClinOncol. 2012; 30(10):1122-28. DOI: 10.1200/JCO.2011.36.8456
18. Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatino with docetaxel as the first-line treatment for patients with IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer [Internet]. Ann Oncol. 2019; 30(12):1978-84. DOI: 10.1093/annoncol/mdz399
19. Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight [Internet]. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188967. DOI: 10.1016/j.bbcan.2023.188967
20. Lu HL, Jie GL, Wu YL. Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials [Internet].
Expert Opin Emerg Drugs. 2022; 27(2):111-26. DOI: 10.1080/14728214.2022.2063836
21. Cáceres H, Varona L, Nenínger E, Basanta D, Duvergel D, Carrillo C, et al. Tratamiento con inhibidores tirosina cinasa en pacientes con cáncer de pulmón [Internet]. Rev Cub de Oncol. 2022 [acceso: 22/12/2023]; 20(1):e173. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/173
22. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang Ch, et al. Erlotinib versus chemotherapy as first -line treatment for patients with advanced EGFR mutation-positive non small- cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open label, randomized, phase III study [Internet]. Lancert Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X
23. Rosell R, Caecereny E, Gervais R, Vergnenegre A, Massuti B, FelipE, et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation- positive non- small cell lung cancer (EURTAC): a multicenter, open -label, randomized phase 3 trial [Internet]. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X
24. Miller V, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, et al. Afatinib versus placebo for patients with advanced, metastatic non-small cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2b/3 randomisedtrial [Internet]. Lancet Oncol. 2012; 13(5):528-38. DOI: 10.1016/S1470-2045(12)70087-6
25.Yang J, Wu Y-L, Shuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatino-based chemotherapy for egfr mutation -positive lung adenocarcinoma (Lux-Lung 3 and Lux-Lung 6): analysis of overall survival data from two randomised, phase 3 trial [Internet]. Lancet Oncol. 2015; 16(2):141-51. DOI: 10.1016/S1470-2045(14)71173-8
26. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, MokT,etal.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [Internet]. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X
27. Tu HY, Wu YL. Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data [Internet]. Futur Oncol. 2020; 16(31):2569-86. DOI: 10.2217/fon-2020-0320
28. Janne PA, Ou SH, Kim DW, Oxnard G, Martins R, Kris M,et al. Dacomitinib as first -line treatment in patients with clinically or molecularly selected advanced non -small cell lung cancer: a multicenter, open- label, phase 2 trial [Internet]. Lancet Oncol. 2014; 15(13):1433-41. DOI: 10.1016/S1470-2045(14)70461-9
29. Wu Y, Cheng Y, Zhou X, Lee K, NakagawaK, Niho S, et al. Dacomitinb versus Gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small cell lung cancer (ARCHER 1050): a randomised, open -label, phase 3 trial [Internet]. Lancet Oncol. 2017; 18(11):1454-66. DOI: 10.1016/S1470-2045(17)30608-3
30. Mok T, Wu YL, Ahn MJ, Garassino M, Kim H, Ramalingam S,et al. Osimertinib or Platinum- pemetrexed in EGFR T790M positive lung cancer [Internet]. NEnglJ Med. 2017; 376(7):629-40. DOI: https://doi.org/10.1056/NEJMoa1612674
31. Popat S, Ahn MJ, Leighl NB, Ramalinga S, Reungwetwattana T, Sira S, et al. Osimertinib for EGFR-mutant non- small cell lung cancer central nervous system metastases: current evidence and future perspertives on therapeutic strategies [Internet]. Target Oncol. 2023; 18(1):9-24. DOI: 10.1007/s11523-022-00941-7
32. Lee JH, Kim EY, Park CK, Lee SY, Lee MK, Yoon SH, et al. Real-World Study of Osimertinib in Korean Patients with Epidermal GrowthFactor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer [Internet]. Cancer Res Treat. 2023; 55(1):112-22. DOI: 10.4143/crt.2022.381
33. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFRMutated Advanced Non-SmallCell Lung Cancer [Internet]. N Eng J Med. 2018; 378(2):11325. DOI: 10.1056/NEJMoa1713137
34. Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [Internet]. NEngl J Med. 2020; 382(1):41-50. DOI: 10.1056/NEJMoa1913662
35. Hung YL, LiuH, Wampfler JA, Tazelaar HD, LiY, Peikert T, et al. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation [Internet]. J Cancer Res Clin Oncol. 2022; 148(8):2099-114. DOI: 10.1007/s00432-021-03766-5
36. Viray H, Vallillo AP, Widick P, Academia E, Shea M, Rangachari D, et al. A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib [Internet]. J Clin Oncol. 2022; 40(16):e21033-e21033.DOI: 10.1200/JCO.2022.40
37. Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data [Internet]. Drugs - Real World Outcomes. 2022; 9(3):333-45. DOI: 10.1007/s40801-022-00302-w
38. Li X, Zhai Z, Zhu Y, Zhou H. Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation [Internet]. Pak J Med Sci. 2022; 38(6):1589-94. DOI: 10.12669/pjms.38.6.5456
39. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [Internet]. N Engl J Med. 2020; 383(18):1711-23. DOI: 10.1056/NEJMoa2027071
40. Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research [Internet]. Pharmacol Res. 2021; 167:105583. DOI: 10.1016/j.phrs.2021.105583
41. Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies [Internet]. Cancers (Basel). 2022; 14(14):3337. DOI: 10.3390/cancers14143337
42. Han X, Liang L, He C, Ren Q, Su J, Cao L, et al. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma [Internet]. BMC Complement Med Ther. 2023; 23(1):422. DOI: 10.1186/s12906-023-04213-3
43. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn J, et al. Genomic Landscape of Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR T790M-Mutant Non-Small Cell Lung Cancer [Internet]. Cancer. 2020; 126(11):2704-12. DOI: 10.1002/cncr.32809
44. Park HR, Kim T, Lee Y, Kim S, Park S, Ju Y et al. Acquired resistance to third-generationEGFR T790M mutant NSCLC [Internet]. J Thorac Oncol. 2021; 16(11):1859-71. DOI: 10.1016/j.jtho.2021.06.013
45. Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, et al. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells [Internet]. Cancer Med. 2022; 11(4):944-55. DOI: 10.1002/cam4.4504
46. Yao Y, Yang H, Zhu B, Wang S, Pang J, Wu X, et al. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non- small-cell lung cancer [Internet]. Respir Res. 2023; 24(1):28. DOI: 10.1186/s12931-023-02329-1
47. Kang J, Deng QM, Feng W, Chen ZH, Su JW, Chen HJ,et al. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer [Internet]. Lung Cancer. 2023; 178:66-74. DOI: 10.1016/j.lungcan.2023.01.017
48. Pasaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR- mutant lung cancer [Internet]. Nat Cancer. 2021; 2(4):377-91. DOI: 10.1038/s43018-021-00195-8
49. He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer [Internet]. Int J Oncol. 2021; 59(5):90. DOI: 10.3892/ijo.2021.5270
50. Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer [Internet]. Cancers (Basel). 2023; 15(2):504. DOI: 10.3390/cancers15020504
51. Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment [Internet]. Int J Mol Sci. 2022; 23(12):6489. DOI: 10.3390/ijms23126489
52. Flores YI, Neninger E, Páramo DL, Ortiz RA, Alfonso S, Alsina SC, et al. Diagnóstico y tratamiento del cáncer de pulmón. Programa Integral para el control del Cáncer en Cuba. La Habana: Editorial Ciencias Médicas; 2020.
53. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR,et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2024; 22(4):249-274. DOI: 10.6004/jnccn.2204.0023
54. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. ESMO Guidelines Committee.Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [Internet]. Ann Oncol. 2023; 34(4):339-57. DOI: 10.1016/j.annonc.2022.12.009
55. Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy [Internet]. Ann Oncol. 2021; 32(12):1637-42. DOI: 10.1016/j.annonc.2021.08.1994
2. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non- small cell lung cancer: Past, present and future [Internet]. World J Clin Oncol. 2021; 12(4):217-37. DOI: 10.5306/wjco.v12.i4.217
3. DeVita VT, Rosenberg SA, Lawrence TS. Cancer Principles & Practice of Oncology. Primer of the molecular biology of cáncer. Third edition. Philadelphia: Editorial Wolters Kluwer; 2021.
4.Wadowska K, Bil-Lula I, Trembecki L, Sliwinska-Mosson M. Genetic markers in lung cancer diagnosis: a review [Internet]. Int J Mol Sci. 2020; 21(13):4569. DOI: 10.3390/ijms21134569
5. Herrera-Juarez M, Serrano-Gomez C, Bote de Cabo H, Paz-Ares L. Targer therapy for lung cáncer: beyong EGFR and ALK [Internet]. Cancer. 2023; 129(12):1803-20. DOI: 10.1002/cncr.34757
6. Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang A, et al. Epidemiologic features of NSCLC gene alterations in Hispanic patients from Puerto Rico [Internet]. Cancers. 2020; 12(12):3492. DOI: 10.3390/cancers12123492
7. Niederhuber J, Armitage J, Doroshow J, Kastan M, Teper J. Abeloff. Oncologíaclínica. 6th edition. España. Editorial Elsevier; 2020.
8. Hubbard SR. EGF receptor inhibition: Attacks on multiple fronts [Internet]. Cancer Cell. 2005; 7(4):287-8. DOI: 10.1016/j.ccr.2005.04.004
9. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al . Epidermal growth factor receptor (EGFR) signaling in cancer [Internet]. Gene. 2006; 366(1):2-16. DOI: 10.106/j.gene.2005.10.018
10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy [Internet]. Nat Rev Cancer. 2004; 4(5):361-70. DOI: 10.1038/nrc1360
11. Dalurzo M, Aviles-Salas A, Soares F, HouY, Li Y, Stroganova A, et al. Testing for EGFR mutations and ALK rearrangements in Advanced Non Small Cell Lung Cancer. Considerations for countries in emerging markets [Internet]. Onco Targets and Therapy. 2021; 14:4671-92. DOI: 10.2147/OTT.S313669
12. Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, et al. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests [Internet]. Clin Lung Cancer. 2020; 21(3):e182-e190. DOI: 10.1016/j.cllc.2019.11.006
13. Rao S, Anthony M, Chowdhry N, Kathrotia R, Mishra M, Naithani M, et al. Molecular Characterization of Lung carcinomas: a study on diagnosis, predictive and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India [Internet]. J Carcinog. 2021; 20:17. DOI: 10.4103/jcar_14_21
14. Thomas R,Weihua Z.Rethink of EGFR in Cancer With Its Kinase Independent Function on Board [Internet]. Front Oncol. 2019; 9:800. DOI: 10.3389/fonc.2019.00800
15. Abourehab M, Alqahtani A, Youssif B, Gouda A. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism [Internet]. Molecules. 2021; 26(21):6677. DOI: 10.3390/molecules26216677
16. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Geftinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma [Internet]. N Engl J Med. 2009; 361(10):947-957. DOI: 10.1056/NEJMoa0810699
17. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinomaof the lung [Internet]. J ClinOncol. 2012; 30(10):1122-28. DOI: 10.1200/JCO.2011.36.8456
18. Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatino with docetaxel as the first-line treatment for patients with IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer [Internet]. Ann Oncol. 2019; 30(12):1978-84. DOI: 10.1093/annoncol/mdz399
19. Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight [Internet]. Biochim Biophys Acta Rev Cancer. 2023; 1878(6):188967. DOI: 10.1016/j.bbcan.2023.188967
20. Lu HL, Jie GL, Wu YL. Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials [Internet].
Expert Opin Emerg Drugs. 2022; 27(2):111-26. DOI: 10.1080/14728214.2022.2063836
21. Cáceres H, Varona L, Nenínger E, Basanta D, Duvergel D, Carrillo C, et al. Tratamiento con inhibidores tirosina cinasa en pacientes con cáncer de pulmón [Internet]. Rev Cub de Oncol. 2022 [acceso: 22/12/2023]; 20(1):e173. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/view/173
22. Zhou C, Wu YL, Chen G, Feng J, Liu X, Wang Ch, et al. Erlotinib versus chemotherapy as first -line treatment for patients with advanced EGFR mutation-positive non small- cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open label, randomized, phase III study [Internet]. Lancert Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X
23. Rosell R, Caecereny E, Gervais R, Vergnenegre A, Massuti B, FelipE, et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation- positive non- small cell lung cancer (EURTAC): a multicenter, open -label, randomized phase 3 trial [Internet]. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X
24. Miller V, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, et al. Afatinib versus placebo for patients with advanced, metastatic non-small cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX- Lung 1): a phase 2b/3 randomisedtrial [Internet]. Lancet Oncol. 2012; 13(5):528-38. DOI: 10.1016/S1470-2045(12)70087-6
25.Yang J, Wu Y-L, Shuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatino-based chemotherapy for egfr mutation -positive lung adenocarcinoma (Lux-Lung 3 and Lux-Lung 6): analysis of overall survival data from two randomised, phase 3 trial [Internet]. Lancet Oncol. 2015; 16(2):141-51. DOI: 10.1016/S1470-2045(14)71173-8
26. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, MokT,etal.Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [Internet]. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X
27. Tu HY, Wu YL. Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data [Internet]. Futur Oncol. 2020; 16(31):2569-86. DOI: 10.2217/fon-2020-0320
28. Janne PA, Ou SH, Kim DW, Oxnard G, Martins R, Kris M,et al. Dacomitinib as first -line treatment in patients with clinically or molecularly selected advanced non -small cell lung cancer: a multicenter, open- label, phase 2 trial [Internet]. Lancet Oncol. 2014; 15(13):1433-41. DOI: 10.1016/S1470-2045(14)70461-9
29. Wu Y, Cheng Y, Zhou X, Lee K, NakagawaK, Niho S, et al. Dacomitinb versus Gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small cell lung cancer (ARCHER 1050): a randomised, open -label, phase 3 trial [Internet]. Lancet Oncol. 2017; 18(11):1454-66. DOI: 10.1016/S1470-2045(17)30608-3
30. Mok T, Wu YL, Ahn MJ, Garassino M, Kim H, Ramalingam S,et al. Osimertinib or Platinum- pemetrexed in EGFR T790M positive lung cancer [Internet]. NEnglJ Med. 2017; 376(7):629-40. DOI: https://doi.org/10.1056/NEJMoa1612674
31. Popat S, Ahn MJ, Leighl NB, Ramalinga S, Reungwetwattana T, Sira S, et al. Osimertinib for EGFR-mutant non- small cell lung cancer central nervous system metastases: current evidence and future perspertives on therapeutic strategies [Internet]. Target Oncol. 2023; 18(1):9-24. DOI: 10.1007/s11523-022-00941-7
32. Lee JH, Kim EY, Park CK, Lee SY, Lee MK, Yoon SH, et al. Real-World Study of Osimertinib in Korean Patients with Epidermal GrowthFactor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer [Internet]. Cancer Res Treat. 2023; 55(1):112-22. DOI: 10.4143/crt.2022.381
33. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFRMutated Advanced Non-SmallCell Lung Cancer [Internet]. N Eng J Med. 2018; 378(2):11325. DOI: 10.1056/NEJMoa1713137
34. Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [Internet]. NEngl J Med. 2020; 382(1):41-50. DOI: 10.1056/NEJMoa1913662
35. Hung YL, LiuH, Wampfler JA, Tazelaar HD, LiY, Peikert T, et al. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation [Internet]. J Cancer Res Clin Oncol. 2022; 148(8):2099-114. DOI: 10.1007/s00432-021-03766-5
36. Viray H, Vallillo AP, Widick P, Academia E, Shea M, Rangachari D, et al. A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib [Internet]. J Clin Oncol. 2022; 40(16):e21033-e21033.DOI: 10.1200/JCO.2022.40
37. Nieva J, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data [Internet]. Drugs - Real World Outcomes. 2022; 9(3):333-45. DOI: 10.1007/s40801-022-00302-w
38. Li X, Zhai Z, Zhu Y, Zhou H. Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation [Internet]. Pak J Med Sci. 2022; 38(6):1589-94. DOI: 10.12669/pjms.38.6.5456
39. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer [Internet]. N Engl J Med. 2020; 383(18):1711-23. DOI: 10.1056/NEJMoa2027071
40. Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research [Internet]. Pharmacol Res. 2021; 167:105583. DOI: 10.1016/j.phrs.2021.105583
41. Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies [Internet]. Cancers (Basel). 2022; 14(14):3337. DOI: 10.3390/cancers14143337
42. Han X, Liang L, He C, Ren Q, Su J, Cao L, et al. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma [Internet]. BMC Complement Med Ther. 2023; 23(1):422. DOI: 10.1186/s12906-023-04213-3
43. Lee J, Kim HS, Lee B, Kim HK, Sun JM, Ahn J, et al. Genomic Landscape of Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR T790M-Mutant Non-Small Cell Lung Cancer [Internet]. Cancer. 2020; 126(11):2704-12. DOI: 10.1002/cncr.32809
44. Park HR, Kim T, Lee Y, Kim S, Park S, Ju Y et al. Acquired resistance to third-generationEGFR T790M mutant NSCLC [Internet]. J Thorac Oncol. 2021; 16(11):1859-71. DOI: 10.1016/j.jtho.2021.06.013
45. Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, et al. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells [Internet]. Cancer Med. 2022; 11(4):944-55. DOI: 10.1002/cam4.4504
46. Yao Y, Yang H, Zhu B, Wang S, Pang J, Wu X, et al. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non- small-cell lung cancer [Internet]. Respir Res. 2023; 24(1):28. DOI: 10.1186/s12931-023-02329-1
47. Kang J, Deng QM, Feng W, Chen ZH, Su JW, Chen HJ,et al. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer [Internet]. Lung Cancer. 2023; 178:66-74. DOI: 10.1016/j.lungcan.2023.01.017
48. Pasaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR- mutant lung cancer [Internet]. Nat Cancer. 2021; 2(4):377-91. DOI: 10.1038/s43018-021-00195-8
49. He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer [Internet]. Int J Oncol. 2021; 59(5):90. DOI: 10.3892/ijo.2021.5270
50. Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer [Internet]. Cancers (Basel). 2023; 15(2):504. DOI: 10.3390/cancers15020504
51. Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Macciò A. EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment [Internet]. Int J Mol Sci. 2022; 23(12):6489. DOI: 10.3390/ijms23126489
52. Flores YI, Neninger E, Páramo DL, Ortiz RA, Alfonso S, Alsina SC, et al. Diagnóstico y tratamiento del cáncer de pulmón. Programa Integral para el control del Cáncer en Cuba. La Habana: Editorial Ciencias Médicas; 2020.
53. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR,et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology [Internet]. J Natl Compr Canc Netw. 2024; 22(4):249-274. DOI: 10.6004/jnccn.2204.0023
54. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. ESMO Guidelines Committee.Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up [Internet]. Ann Oncol. 2023; 34(4):339-57. DOI: 10.1016/j.annonc.2022.12.009
55. Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy [Internet]. Ann Oncol. 2021; 32(12):1637-42. DOI: 10.1016/j.annonc.2021.08.1994
Publicado
01.10.2024
Cómo citar
1.
Flores Vega YI, Páramo González DL, Perez Fonteboa A, Martínez Ávila DR. Tratamiento del cáncer de pulmon portador de la mutación del receptor del factor de crecimiento epidérmico. Rev Cubana Med Milit [Internet]. 1 de octubre de 2024 [citado 29 de enero de 2025];53(4):e024044871. Disponible en: https://revmedmilitar.sld.cu/index.php/mil/article/view/44871
Número
Sección
Artículo de Revisión
Licencia
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cual estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons. Los contenidos que aquí se exponen pueden ser compartidos, copiados y redistribuidos en cualquier medio o formato. Pueden ser adaptados, remezclados, transformados o creados otros a partir del material, mediante los siguientes términos: Atribución (dar crédito a la obra de manera adecuada, proporcionando un enlace a la licencia, e indicando si se han realizado cambios); no-comercial (no puede hacer uso del material con fines comerciales) y compartir-igual (si mezcla, transforma o crea nuevo material a partir de esta obra, podrá distribuir su contribución siempre que utilice la misma licencia que la obra original).
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada.
